Welcome to the Institute of Clinical Research

Welcome to the Institute of Clinical Research

About Us

The Institute of Clinical Research (ICR) is the probably the oldest independent membership-led professional body for global clinical researchers.  

For over 40 years, The Institute of Clinical Research (ICR) has provided high quality training, networking and support to the clinical research community.  For many Members the Institute has been part of their life throughout their working careers, many have been with the Institute since its first incarnation as the ACRPI.

It is the membership that makes the Institute.

How does it all work ?

The Institute of Clinical Research is you, the Membership governed by the Articles of Memorandum drawn up by the founding members.

The Board is made up of members who give their time freely to guide the future direction of the ICR.

The ICR Secretariat is the administrative arm of the Institute, its primary focus is to ensure that the wishes of the Board and Membership are carried out and to see to the day to day tasks that any membership organisation generates.

  

Our Mission

The ICR exists to support our members through all stages of their careers. We do this, in part, by:

  • Defining and refining standards for our profession
  • Providing a forum for discussion of key issues impacting clinical research
  • Promoting good relations with other healthcare related groups 
  • Providing opportunities for learning and development to enhance professional competence 
  • Enhancing public confidence and understanding of clinical research

 

Current News

10 clinical trials to watch in the first half of 2023

By ICR Secretariat / 19/01/2023 03:56 PM

The biotechnology industry begins 2023 at a crossroads.

In many ways, the sector is coming off of one of its toughest years in recent memory. Initial …

'The Top Line': FDA's stance on cancer drug approval, plus this week's headlines

By ICR Secretariat / 19/01/2023 03:55 PM

The FDA is making some changes in the accelerated approval process. In this episode, we’ll discuss the recent changes with the FDA’s regulation of can…

5 questions facing gene therapy in 2023

By ICR Secretariat / 19/01/2023 03:53 PM

Sometime before the end of March, a person with the inherited blood disease beta thalassemia will receive an infusion containing hundreds of millions …


Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

By ICR Secretariat / 12/12/2022 04:03 PM

As the corporate world evolves in the wake of COVID-19, Sanofi has christened an innovative headquarters to help keep pace.

Navigate the complexities of cell and gene therapies

By ICR Secretariat / 12/12/2022 02:16 PM

For cell and gene therapies, all stages of the drug development life cycle are complex. The patient, product and supply chain requires specialized set…

Pfizer CEO Bourla stung by UK's pharma marketing regulator over kids' COVID vax claims: report

By ICR Secretariat / 12/12/2022 01:49 PM

Pfizer’s chief executive Albert Bourla, Ph.D., is in hot water for claims he made during a BBC interview late last year about the company's then-unapp…


FDA grants speedy review to Sarepta’s Duchenne gene therapy

By ICR Secretariat / 01/12/2022 02:38 PM

The Food and Drug Administration has started the first regulatory review of a gene therapy for Duchenne muscular dystrophy, the treatment’s developer,…

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

By ICR Secretariat / 01/12/2022 02:37 PM

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875…

Navigate the complexities of cell and gene therapies

By ICR Secretariat / 01/12/2022 02:36 PM

For cell and gene therapies, all stages of the drug development life cycle are complex. The patient, product and supply chain requires specialized set…


Infex begins study of pseudomonas aeruginosa candidate RESP-X

By ICR Secretariat / 29/11/2022 01:25 PM

Phase 1 research will evaluate tolerability and safety of therapy among healthy volunteers

Infex – a company focusing on anti-infectives specialist – …

Pfizer, BioNTech start study testing next COVID-19 vaccine

By ICR Secretariat / 29/11/2022 01:24 PM

  • Pfizer and BioNTech on Thursday announced the start of a Phase 1 study of a new COVID-19 vaccine candidate designed to spur a broader and potentially…

With Sanofi as its marketing partner, Provention Bio grabs long-awaited FDA nod for diabetes drug

By ICR Secretariat / 29/11/2022 12:20 PM

What a long, strange trip it’s been for teplizumab, a drug developed to combat juvenile diabetes—36 years to be exact.


Under FDA pressure, GSK limits use of ovarian cancer drug

By ICR Secretariat / 21/11/2022 11:11 AM

GSK will stop selling the drug Zejula for some ovarian cancer patients whose disease is stable after a second line of chemotherapy, the company said F…

A new way to access scientific papers?

By ICR Secretariat / 21/11/2022 11:05 AM

Many researchers are surprised to find that leaving university also means leaving behind something they didn’t expect—easy access to peer-reviewed lit…

Trial failures end latest hope for Roche’s Alzheimer’s drug

By ICR Secretariat / 21/11/2022 10:59 AM

An experimental Alzheimer’s disease medicine from Roche failed two large Phase 3 clinical trials, a major setback to the Swiss company’s yearslong eff…


Healthcare Twitter influencers beam over Pfizer's RSV shot data: report

By ICR Secretariat / 15/11/2022 12:12 PM

Move over, COVID: Shots to stop respiratory syncytial virus (RSV) are providing the new must-watch trial data on Twitter as healthcare influencers on …

Galapagos to cut 200 jobs amid research revamp

By ICR Secretariat / 15/11/2022 12:07 PM

The workforce reduction is part of a “new strategic direction” for Galapagos, which intends to stop developing drugs for fibrosis and kidney disease.

Eli Lilly, Boehringer Ingelheim bolster case for Jardiance to treat chronic kidney disease

By ICR Secretariat / 15/11/2022 12:05 PM

With an FDA approval 19 months ago to treat chronic kidney disease, AstraZeneca’s Farxiga dominated the race against its primary SGLT2 rival—Eli Lilly…


Pfizer planning steep price hike for COVID-19 vaccine

By ICR Secretariat / 01/11/2022 03:51 PM

Pfizer is considering hiking the price of its COVID-19 vaccine by roughly four times what it currently charges as it prepares for sales in the U.S. to…

Cancer patients want pharma's support, but many aren’t getting it: survey

By ICR Secretariat / 01/11/2022 03:49 PM

Education and support are critical to getting—and keeping—patients on appropriate therapy. But many oncology patients have gaps in their knowledge of …

ICR’s new study tracks disease progression in children with rare type of cancer

By ICR Secretariat / 01/11/2022 03:48 PM

Blood tests could help guide the treatment of children with the cancer rhabdomyosarcoma (RMS), according to a new study led by scientists at the Insti…


Novo Nordisk's Wegovy gets a surprise endorsement from Twitter's soon-to-be owner Elon Musk

By ICR Secretariat / 20/10/2022 04:04 PM

How do you solve a problem like Elon Musk? Well, when it comes to his weight, there seems to be a simple answer: Novo Nordisk’s Wegovy.

GSK sets high bar with trial results for RSV vaccine

By ICR Secretariat / 20/10/2022 02:08 PM

  • GSK’s vaccine for respiratory syncytial virus proved strongly effective in a large Phase 3 trial, reducing cases of lower respiratory infection in pe…

Atara on verge of landmark approval for first allogeneic T-cell therapy

By ICR Secretariat / 20/10/2022 01:56 PM

With a thumbs up from Europe’s Committee for Medicinal Products for Human Use (CHMP), Atara Biotherapeutics’ Ebvallo is poised to become the first all…


OPTIMA announce AstraZeneca and Mutabor as official partners

By ICR Secretariat / 13/10/2022 02:53 PM

The companies will aim to improve treatment for patients with prostate, breast and lung cancer

The Innovative Medicines Initiative (IMI) – a joint und…

'The Top Line': Will Eisai's Alzheimer's med lecanemab sway the CMS, how Pfizer is upping its DTC ad push for its COVID shots

By ICR Secretariat / 13/10/2022 02:45 PM

Eisai and Biogen's Alzheimer’s disease drug lecanemab did surprisingly well in a phase 3 trial. The results support the idea that an anti-amyloid drug…

Course Postponements Due to Covid

By ICR Secretariat / 10/02/2022 03:38 PM

All of our delegates and members who had course places postponed over the last two years due to covid restrictions/illness have now been contacted dir…




Events and Courses

The Essentials of Trial Master File (TMF) Management M4

Online payments currently temporarily suspended. To make a payment please contact&nbsp;<a href="http://office@icr-global.org/" style="backgroun...


Essentials of Clinical Trial Monitoring M1

Online payments currently temporarily suspended. To make a payment please contact office@icr-global.org&n...


Data Management for Clinical Researchers M10

Online payments currently temporarily suspended. To make a payment please contact&nbsp;<a href="http://office@icr-global.org/" style="background-...


Effective Project Management for Clinical Trials (3 Days ) M5

Online payments currently temporarily suspended. To make a payment please contact&nbsp;<a href="http://office@icr-global.org/" style="background-...


Clinical Trial Administration - Beyond the Basics M8

Online payments currently temporarily suspended. To make a payment please contact&nbsp;<a href="http://office@icr-global.org/" style="background-...


Advanced Monitoring M3

Online payments currently temporarily suspended. To make a payment please contact&nbsp;<a href="http://office@icr-global.org/" style="backgroun...


Current Jobs